Literature DB >> 20649452

What have we learned from the IL28 receptor knockout mouse?

Markus Mordstein1, Thomas Michiels, Peter Staeheli.   

Abstract

The recently discovered type III interferons (IFNs), also known as IFN-lambda, are part of the early innate immune response against viral infections. The IFN-lambda system closely resembles the type I IFN (IFN-alpha/beta) system in terms of expression after virus infection as well as intracellular signaling and activation of antiviral host factors in susceptible cells. However, in contrast to type I IFN, which signals through a universally expressed cell surface receptor, IFN-lambda uses a distinct receptor complex (IL28R) for signaling, which is expressed on a limited range of cell types. Until recently both the contribution of type III IFN to antiviral resistance as well as the exact nature of IL28R-expressing cells in vivo remained elusive. In this review we discuss data obtained from the experiments with IL28Ralpha(0/0) mice that demonstrated the role of IFN-lambda in viral defense in vivo. We further discuss the experiments that identified the cell types in various organs that express functional IFN-lambda receptors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20649452     DOI: 10.1089/jir.2010.0061

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  16 in total

1.  IFN type I and type II independent enhancement of B cell TLR7 expression by natural killer cells.

Authors:  Suwan Sinha; Yuhong Guo; Suwannee Thet; Dorothy Yuan
Journal:  J Leukoc Biol       Date:  2012-05-25       Impact factor: 4.962

2.  LncRNA260-specific siRNA targeting IL28RA gene inhibit cardiomyocytes hypoxic/reoxygenation injury.

Authors:  Ge Gong; Xin-Xing Yang; Yanyan Li; Hong-Yu Geng; Zhi-Jian Yang; Lian-Sheng Wang; Hyun Jun Kim; Xin-Zheng Lu
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

Review 3.  Interferon-lambda: a new addition to an old family.

Authors:  Raymond P Donnelly; Sergei V Kotenko
Journal:  J Interferon Cytokine Res       Date:  2010-08       Impact factor: 2.607

4.  Activation of type III interferon genes by pathogenic bacteria in infected epithelial cells and mouse placenta.

Authors:  Hélène Bierne; Laetitia Travier; Tanel Mahlakõiv; Ludovic Tailleux; Agathe Subtil; Alice Lebreton; Anupam Paliwal; Brigitte Gicquel; Peter Staeheli; Marc Lecuit; Pascale Cossart
Journal:  PLoS One       Date:  2012-06-14       Impact factor: 3.240

Review 5.  Interferon-λ: Immune Functions at Barrier Surfaces and Beyond.

Authors:  Helen M Lazear; Timothy J Nice; Michael S Diamond
Journal:  Immunity       Date:  2015-07-21       Impact factor: 31.745

6.  Differential host response, rather than early viral replication efficiency, correlates with pathogenicity caused by influenza viruses.

Authors:  Peter S Askovich; Catherine J Sanders; Carrie M Rosenberger; Alan H Diercks; Pradyot Dash; Garnet Navarro; Peter Vogel; Peter C Doherty; Paul G Thomas; Alan Aderem
Journal:  PLoS One       Date:  2013-09-20       Impact factor: 3.240

7.  S. mansoni bolsters anti-viral immunity in the murine respiratory tract.

Authors:  Sebastian Scheer; Christine Krempl; Carsten Kallfass; Stefanie Frey; Thilo Jakob; Gabriel Mouahid; Hélène Moné; Annette Schmitt-Gräff; Peter Staeheli; Marinus C Lamers
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

8.  Interleukin-29 modulates proinflammatory cytokine production in synovial inflammation of rheumatoid arthritis.

Authors:  Fang Wang; Lingxiao Xu; Xiaoke Feng; Dunming Guo; Wenfeng Tan; Miaojia Zhang
Journal:  Arthritis Res Ther       Date:  2012-10-19       Impact factor: 5.156

Review 9.  Antiviral type I and type III interferon responses in the central nervous system.

Authors:  Frédéric Sorgeloos; Marguerite Kreit; Pascale Hermant; Cécile Lardinois; Thomas Michiels
Journal:  Viruses       Date:  2013-03-15       Impact factor: 5.048

Review 10.  The bacterial pathogen Listeria monocytogenes and the interferon family: type I, type II and type III interferons.

Authors:  Olivier Dussurget; Hélène Bierne; Pascale Cossart
Journal:  Front Cell Infect Microbiol       Date:  2014-04-28       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.